Sartorius Stedim Biotech (OTCMKTS:SDMHF) Now Covered by HSBC

Equities research analysts at HSBC began coverage on shares of Sartorius Stedim Biotech (OTCMKTS:SDMHFGet Rating) in a research note issued to investors on Wednesday, The Fly reports. The firm set a “buy” rating on the stock.

A number of other research analysts have also recently issued reports on SDMHF. UBS Group raised Sartorius Stedim Biotech from a “sell” rating to a “buy” rating in a research note on Monday, May 16th. Morgan Stanley started coverage on Sartorius Stedim Biotech in a research note on Thursday, March 31st. They issued an “equal weight” rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Sartorius Stedim Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $550.00.

OTCMKTS SDMHF opened at $288.69 on Wednesday. The stock has a 50-day simple moving average of $329.88 and a 200 day simple moving average of $397.29. Sartorius Stedim Biotech has a 12 month low of $282.50 and a 12 month high of $653.00.

About Sartorius Stedim Biotech (Get Rating)

Sartorius Stedim Biotech SA produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products.

Read More

The Fly logo

Analyst Recommendations for Sartorius Stedim Biotech (OTCMKTS:SDMHF)

Receive News & Ratings for Sartorius Stedim Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius Stedim Biotech and related companies with's FREE daily email newsletter.